


## Booster allergen immunotx cuts symptoms in allergic rhinitis

July 14 2017



(HealthDay)—For patients with grass pollen-induced allergic rhinitis



(AR), booster allergen immunotherapy (AIT) using tyrosine-absorbed grass pollen allergoids containing the adjuvant monophosphoryl lipid A (MPL) prevents symptom recurrence, according to a study published online July 4 in *Allergy*.

Oliver Pfaar, M.D., from Heidelberg University in Germany, and colleagues examined the clinical effects of a preseasonal, ultra-short-course booster AIT on clinical outcome parameters in patients aged ≥12 years with recurrent grass pollen-induced seasonal AR who had completed a successful course of any grass pollen AIT at least five years before enrollment; 56 received one preseasonal short-course booster AIT, and 51 control patients received symptomatic medication.

The researchers found that the booster AIT group had significantly lower combined symptom and medication scores in the peak grass pollen season ( $\Delta = 38.4$  percent; P booster AIT was generally well-tolerated; mild, grade 1 systemic adverse events were reported by two patients.

"Booster AIT using tyrosine-absorbed allergoids containing the adjuvant MPL effectively prevents re-occurrence of symptoms in <u>patients</u> with grass <u>pollen</u>-induced AR," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Bencard, which sponsored the study.

**More information:** Abstract

Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: Booster allergen immunotx cuts symptoms in allergic rhinitis (2017, July 14) retrieved 2 May 2024 from <a href="https://medicalxpress.com/news/2017-07-booster-allergen-immunotx-symptoms-">https://medicalxpress.com/news/2017-07-booster-allergen-immunotx-symptoms-</a>



## allergic.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.